Effect of temporal sampling protocols on myocardial blood flow measurements using Rubidium-82 PET

S. S. Koenders, MSc, a,d J. D. van Dijk, MSc, PhD, a P. L. Jager, MD, PhD, a M. Mouden, MD, PhD, c A. G. Tegelaar, BSc, a C. H. Slump, PhD, d and J. A. van Dalen, PhD b

a Department of Nuclear Medicine, Isala Hospital, Zwolle, The Netherlands
b Department of Medical Physics, Isala hospital, Zwolle, The Netherlands
c Department of Cardiology, Isala hospital, Zwolle, The Netherlands
d Technical Medical Center, University of Twente, Enschede, The Netherlands

Received Oct 7, 2020; accepted Jan 19, 2021
doi:10.1007/s12350-021-02555-4

Background. A variety of temporal sampling protocols is used worldwide to measure myocardial blood flow (MBF). Both the length and number of time frames in these protocols may alter MBF and myocardial flow reserve (MFR) measurements. We aimed to assess the effect of different clinically used temporal sampling protocols on MBF and MFR quantification in Rubidium-82 (Rb-82) PET imaging.

Methods. We retrospectively included 20 patients referred for myocardial perfusion imaging using Rb-82 PET. A literature search was performed to identify appropriate sampling protocols. PET data were reconstructed using 14 selected temporal sampling protocols with time frames of 5-10 seconds in the first-pass phase and 30-120 seconds in the tissue phase. Rest and stress MBF and MFR were calculated for all protocols and compared to the reference protocol with 26 time frames.

Results. MBF measurements differed ($P \leq 0.003$) in six (43%) protocols in comparison to the reference protocol, with mean absolute relative differences up to 16% (range 5%-31%). Statistically significant differences were most frequently found for protocols with tissue phase time frames < 90 seconds. MFR did not differ ($P \geq 0.11$) for any of the protocols.

Conclusions. Various temporal sampling protocols result in different MBF values using Rb-82 PET. MFR measurements were more robust to different temporal sampling protocols. (J Nucl Cardiol 2022;29:1729–41.)

Key Words: Myocardial blood flow • PET myocardial perfusion imaging • $^{82}$rb • temporal sampling • regadenoson
INTRODUCTION

Quantification of myocardial blood flow (MBF) and myocardial flow reserve (MFR) using Rubidium-82 (Rb-82) PET is increasingly used in daily clinical practice. It provides valuable prognostic information in addition to the visual evaluation of myocardial perfusion imaging (MPI) PET data in the detection and evaluation of coronary artery disease (CAD).1–5 The increasing use of MBF and MFR quantification among multiple hospitals performing Rb-82 PET MPI and the lack of consensus in literature and guidelines on reconstruction protocols has led to a wide variety of temporal sampling protocols that could limit accuracy and data comparison between centers.6,7

A temporal sampling protocol is used to reconstruct dynamic images. These dynamic images are then used to determine the tracer activity concentration in the blood pool (left ventricle (LV)) and myocardial tissue over time in order to quantify MBF and MFR.3 It is important that these measurements are accurate as the resulting time–activity curves (TACs) are used as input for compartmental analysis to calculate the MBF.3,8,9 Both the length and the number of time frames in the temporal sampling protocol may influence the measured TACs and may therefore alter MBF and MFR measurements.10

In order to interchange and interpret MBF and MFR values across different centers, it is important to know the effect of temporal sampling on absolute MBF and MFR measurements. Therefore, our aim was to assess the effect of various clinically used temporal sampling protocols on MBF and MFR quantification.

MATERIALS AND METHODS

Temporal Sampling Protocol Selection

A literature search was performed using the Scopus database to find articles available in September 2020. The search strategy to identify all possible temporal sampling protocols used in clinical practice involved the use of the following terms in the title, keywords or abstract: “Rubidium” or “Rb,” and “myocardial blood flow” or “MBF” or “flow,” and “quantification” or “sampling” or “dynamic” or “time frame” or “frame time,” and not “dog” or “canine” or “rabbit,” or “animal.” The full texts of all the articles that were found were screened for temporal sampling protocols used for Rb-82 PET MPI. Exclusion criteria were study populations consisting of animals and phantom or simulation studies. Furthermore, Lee et al. suggest not to use time frames < 5s during the first-pass (blood pool) phase, as these may contain inadequate count statistics.6,10 Therefore, protocols using time frames < 5s during the first-pass phase were excluded. Protocols using time frames > 10 seconds in the first-pass phase were also excluded as these are likely to result in under-sampling of the left ventricle TAC.3

Study Design

We retrospectively included 20 patients referred for MPI using Rb-82 PET/CT (Vereos, Philips Healthcare) who underwent dynamic rest and regadenoson-induced stress imaging. These 20 patients comprised 10 patients with a scan interpreted as normal by a nuclear medicine physician and 10 in whom the Rb-82 PET scan was interpreted as abnormal (ischemic or irreversible defect). In this way, we ensured the applicability not only in patient scans interpreted as normal but also in patient scans with less perfusion. Approval by the medical ethics committee was not required according to Dutch law as this study was performed retrospectively. Nevertheless, all patients provided written informed consent for the use of their data for research purposes.

Patient Preparation and Data Acquisition

All subjects were asked to abstain from caffeine-containing substances for 24 hours and to discontinue dipyridamole-containing medication for 48 hours before imaging. Preceding to MPI, a low-dose CT scan was acquired using 1.5 seconds rotation time, a pitch of 0.83, a collimation of 64 × 0.625 mm, a tube voltage of 120 kV, and a tube current of 22 mA. Next, 740 MBq Rb-82 was administered intravenously with a flow rate of 50 mL/min using a Strontium-82/Rb-82 generator (CardioGen-82, Bracco Diagnostics Inc.). Ten minutes after the first elution, we induced pharmacological stress by administering 400 l g (5 mL) of regadenoson over 10 seconds. After a 5 mL saline flush (NaCl 0.9%), we administered a second dose of 740 MBq Rb-82. We acquired seven-minute PET list-mode acquisitions on the PET system after both Rb-82 administrations. CT-
based attenuation correction was applied after registration of CT and PET data.

**Data Processing**

CT data were reconstructed using an iterative reconstruction method (iDose level 4) and a slice thickness of 3 mm. PET images were reconstructed with 3D ordered subset expectation maximization (OSEM) using 2 iterations and 15 subsets and a 3D Gaussian post-smoothing filter of 6 mm. Corrections were performed for decay, attenuation, scatter and random coincidences, and dead time effects. The reconstructed dynamic images were post-processed by the same experienced operator using Corridor4DM software (v2017).

Myocardium contours were automatically detected in both rest and stress scans based on the static images which were reconstructed from the data acquired between 2:30 and 7:00 minutes (tissue phase). Furthermore, a region of interest (ROI) was automatically placed in the images. If needed, this ROI was manually replaced to the location of the mitral valve to estimate the activity in the blood pool as shown in Figure 1. This was done by assigning an imaginary line between the septal and lateral wall which has to run through the center of the ROI as shown in Figure 1. We manually checked and corrected the dynamic images for the presence or myocardial creep. The activity concentrations in the myocardium contour and ROI were measured in the reconstructed time frames of the different temporal sampling protocols to calculate the TACs for the LV, the whole myocardium (global), and the three vascular territories: left anterior descending (LAD), left circumflex (LCX), and right coronary artery (RCA). The one-tissue compartment (1-TCM) model of Lortie et al. based on an ROI methodology was used to calculate the absolute MBF from the TACs using Corridor4DM. Furthermore, the MFR, defined as the...
stress MBF divided by the rest MBF, was automatically calculated as well.

The protocol stated to be most optimal by Lee et al. uses 26 frames (24 × 5 seconds, 2 × 120 seconds) and was used as reference. \(^{10}\) MBF values were excluded in case of an unreliable TAC when using the reference protocol. An unreliable TAC was defined as a TAC without a clear LV peak during the first-pass phase when activity reaches the LV, or a lack of steady state during the tissue phase when the activity is only present in the myocardium, as explained by Koenders et al. \(^{12}\) We post-processed the reference protocol (26A) a second time (26A*) to ascertain the reproducibility of post-processing the data. Absolute relative differences in rest MBF, stress MBF, and MFR measurements as compared to the values obtained using the reference protocol were calculated and classified into two categories: ≤ 10% and > 10%.

**Statistical Analysis**

Patient-specific parameters and characteristics were determined as percentage or mean ± standard deviation (SD). For each patient, we calculated rest MBF, stress MBF, and MFR for the reference protocol as well as for the 14 selected protocols. We compared these three measurements for each of the 14 protocols to the reference protocol using the Wilcoxon signed rank test using SPSS Statistics version 24.0 (IBM Corporation). Following a Bonferroni correction for the 14 different comparisons, the level of statistical significance was set to 0.05/14 = 0.004 for all statistical analyses.
RESULTS

We screened 112 articles finding 62 potentially relevant articles containing temporal sampling protocols, as shown in Figure 2. Upon additional review, this resulted in 15 different temporal sampling protocols that were applied to patient data, including the reference protocol referred by 26A, as shown in Table 1 and Figure 3. The baseline characteristics of the included patients are summarized in Table 2.

We found a good reproducibility for the reference protocol as the mean absolute relative differences were ≤4.1% as shown in Figure 4. Neither the MBF nor the MFR measurements differed significantly after Bonferroni correction (P > 0.01), as shown in Figure 5.

Six out of the 14 (43%) temporal sampling protocols resulted in different global rest and stress MBF (P ≤ 0.003) as compared to the reference protocol. The corresponding protocols were those with 22, 27 (A), 30, 31, 32, and 48 frames as shown in Table 3 and Figure 5. Significant differences in MBF were found for these six protocols which all use time frames < 90 seconds in the tissue phase instead of 120 seconds as used in the reference protocol. Compared to the reference, none of the tested protocols showed a difference (P ≥ 0.15) in global MFR measurements. Median values with interquartile ranges of the MBF and MFR measurements for all 20 patients obtained using the different temporal sampling protocols and the mean absolute relative differences to the reference protocol with ranges are given in Table 3.

In addition, protocols using 20, 23, 26 (C), and 30 frames showed absolute relative differences of ≤10% for just rest or stress MBF.

On a regional level, both rest and stress MBF differed (P ≤ 0.002) in all regional territories (LAD, LCX, and RCA) for the protocols using 22, 27 (A), 31, 32, and 48 frames. Median values with interquartile ranges of regional MBF and MFR values obtained using the different temporal sampling protocols and the mean absolute relative differences to the reference protocol with ranges are given in the Appendix. Results on a
regional level were in agreement with the results found for global rest and stress MBF. Compared to the reference, none of the tested protocols showed a significant difference ($P \geq 0.11$) in regional MFR measurements.

**DISCUSSION**

In this study, we selected temporal sampling protocols used in Rb-82 PET MPI from the literature and assessed the effect on absolute blood flow measurements. We showed that the use of various temporal sampling protocols can result in different rest and stress MBF, both on a regional and global level. We found mean absolute relative differences up to 13% for global MBF and up to 16% for regional MBF in comparison to the reference protocol. No significant differences were found for global or regional MFR.

Several studies have reported the importance of accurate temporal sampling of the first-pass phase for MBF quantification.\textsuperscript{3,8–10} The temporal sampling protocol that we used as reference was stated by Lee et al. to optimally sample the blood pool TAC.\textsuperscript{10} This protocol uses 24 5-second frames for the first-pass and intermediate (activity in both LV and myocardium) phase. Furthermore, the protocol uses 2 frames of 120 seconds for the tissue phase (activity mainly present in the myocardium) as it was shown that such long frame durations hardly affect MBF measurements.\textsuperscript{10} In our study, differences in MBF were most frequently found for the protocols with time frames less than 90 seconds in the tissue phase instead of 120 seconds as used in the reference protocol. More specifically, it seems that small variations in the input function alter MBF measurements, presumably due to insufficient count statistics during the tissue phase. Yet the protocol with 18 frames was the only protocol that uses time frames less than 90 seconds for which we did not find a significant difference in MBF. As we found a good reproducibility for the reference protocol, it is unlikely that the manual relocation of the ROI or the myocardial contours caused

**Table 1.** Overview of the 14 tested temporal sampling protocols and the reference protocol (26A) that was post-processed twice (26A*)

| Number of frames | Frame lengths |
|------------------|---------------|
| 14               | 9 x 10 seconds | 3 x 30 seconds | 1 x 60 seconds | 1 x 120 seconds |
| 16               | 12 x 10 seconds | 2 x 30 seconds | 1 x 60 seconds | 1 x 120 seconds |
| 18               | 1 x 10 seconds | 8 x 5 seconds | 3 x 10 seconds | 2 x 20 seconds | 4 x 60 seconds |
| 20               | 12 x 8 seconds | 5 x 12 seconds | 1 x 30 seconds | 1 x 60 seconds | 1 x 120 seconds |
| 22               | 18 x 10 seconds | 4 x 60 seconds |
| 23               | 15 x 6 seconds | 5 x 12 seconds | 1 x 30 seconds | 1 x 60 seconds | 1 x 120 seconds |
| 26A & 26A*       | 24 x 5 seconds | 2 x 120 seconds |
| 26B              | 12 x 5 seconds | 6 x 10 seconds | 4 x 20 seconds | 4 x 40 seconds |
| 26C              | 18 x 5 seconds | 6 x 15 seconds | 1 x 120 seconds | 1 x 60 seconds |
| 27A              | 20 x 6 seconds | 4 x 30 seconds | 3 x 60 seconds |
| 27B              | 14 x 5 seconds | 6 x 10 seconds | 3 x 20 seconds | 3 x 30 seconds | 1 x 90 seconds |
| 30               | 16 x 5 seconds | 6 x 10 seconds | 3 x 20 seconds | 4 x 30 seconds | 1 x 80 seconds |
| 31               | 20 x 6 seconds | 5 x 12 seconds | 4 x 30 seconds | 2 x 60 seconds |
| 32               | 24 x 5 seconds | 8 x 30 seconds |
| 48               | 36 x 5 seconds | 8 x 15 seconds | 4 x 30 seconds |

**Table 2.** Baseline characteristics of all included patients presented as mean ± SD or percentage

| Characteristic | All patients (n=20) |
|---------------|---------------------|
| Age (years)   | 67 ± 9              |
| Male gender (%) | 80                  |
| Weight (kg)   | 87 ± 15             |
| Length (cm)   | 177 ± 8             |
| BMI (kg/m$^2$) | 27.7 ± 4.3          |
| Current smoker (%) | 5                  |
| Hypertension (%) | 45                 |
| Dyslipidaemia (%) | 40               |
| Diabetes (%)  | 30                  |
| Family history (%) | 55              |
the differences in MBF measurements. Possibly, deviating MBFs might partly be explained by time frames which are too small or too large in the intermediate phase in combination with shorter time frames in the tissue phase. The effect of time framing during the first-pass phase was expected to be limited as we only used frames of 5-10 seconds in this phase.10

Compared to the reference, none of the tested protocols showed a significant difference in global or regional MFR measurements. As the MFR is the ratio between stress and rest MBF, it seems to correct for systemic biases of rest and stress MBF introduced by several temporal sampling protocols (Figure 5). However, as MFR is defined as the ratio between stress and rest MBF, error propagation might cause the variance of MFR measurements to exceed the variance of MBF measurements.14 This likely explains that for some protocols (14, 16, and 20), we observed more patients with an absolute relative difference > 10% for MFR than for rest or stress MBF (Figure 4). Furthermore, conflicting studies exist regarding the preference for stress MBF or MFR for risk stratification of patients with suspected CAD. Several studies found that stress MBF is superior to MFR, 15–17 while others found that the MFR is superior to stress MBF for risk stratification.1,3–5,18 Murthy et al. 19 and Tahari et al. 20 reported that MFR was more consistent when different software is used and when different methods are used to determine the input function. Moreover, MFR was shown to be more robust in case of different advanced reconstruction settings as compared to MBF values.21 In our study, MFR measurements were clearly less dependent on the temporal sampling protocol as compared to MBF measurements, which supports MFR as the preferred parameter.

Figure 4. Barplot showing the percentage of patients with absolute relative differences >10% in A global rest MBF (mL/min/g), B global stress MBF (mL/min/g), and C global MFR for all tested protocols as compared to the reference protocol that was post-processed twice (26A*). The absolute number of patients is shown within the bars.
Figure 5. Boxplots of the 14 tested temporal sampling protocols and the boxplot showing the reproducibility (26A*) with the MBF and MFR values of each patient (gray dots) and the median value (dark blue line) representing the reference protocol (26A, blue) for global rest (A) and stress (B) MBF and MFR (C). *P < 0.004.
There are several limitations to this study that should be recognized. First, it was not possible to evaluate the effect of different temporal sampling protocols on the diagnostic accuracy due to the lack of a reference standard and the relatively small sample size. However, we did use an optimized temporal sampling protocol suggested by Lee et al. as a reference and performed a pair-wise comparison, limiting the need for a large sample size.

Secondly, we used a relatively low Rb-82 activity (740 MBq) as compared to the generally recommended activity of 1110 MBq. This relatively low amount of activity is sufficient for MBF quantification using the Vereos PET scanner which contains sensitive silicon photomultipliers with digital readout. Higher activities than 740 MBq will presumably result in better count statistics during the tissue phase and could therefore result in a better image quality. However, higher activities may hamper blood flow quantification when using PET scanners with photomultiplier tubes that have a low count-rate performance. If the activities administered exceed the dynamic range of the PET scanner, it will lead to an underestimation of the count-rate during the first-pass phase which will influence the TAC and therefore alter flow measurements. Nevertheless, if we had used a higher activity in all our patients, the count statistics during the tissue phase would be better which would possibly result in less MBF variation when using protocols with shorter time frames in the tissue phase as compared to the reference protocol. However, as previous studies showed that there is no added value in using shorter time frames during the tissue phase, we do not recommend these protocols.

Finally, we tested temporal sampling protocols only using the 1-TCM of Lortie et al. as this model is most commonly used for Rb-82. Therefore, we did not include other 1-TCMs with different extraction functions or other compartmental models such as the two-compartment model and the retention model.

### Table 3. Global flow values and mean absolute relative differences for all 14 protocols in comparison to the reference protocol that was post-processed twice (26A and 26A*)

|     | Flow values                  | Mean absolute relative difference |
|-----|------------------------------|----------------------------------|
|     | Stress MBF (mL/min/g)        | Rest MBF (mL/min/g)              | Stress MBF (%) | Rest MBF (%) | MFR (%) |
| 14  | 1.98 [1.55–2.49]             | 0.83 [0.68–0.97]                | 2.34 [2.15–2.80]| 4.9 (1–13)  | 3.7 (0–11)  | 6.8 (0–16)  |
| 16  | 1.95 [1.52–2.41]             | 0.81 [0.65–0.95]                | 2.40 [2.13–2.78]| 4.2 (1–14)  | 4.1 (0–11)  | 6.5 (1–17)  |
| 18  | 2.04 [1.67–2.44]             | 0.84 [0.72–1.02]                | 2.42 [2.07–2.85]| 4.0 (0–15)  | 5.1 (0–15)  | 6.2 (1–15)  |
| 20  | 1.90 [1.61–2.26]             | 0.83 [0.69–0.94]                | 2.49 [2.14–2.71]| 3.9 (0–12)  | 3.6 (0–10)  | 4.8 (0–17)  |
| 22  | 1.81 [1.37–2.33]             | 0.78 [0.61–0.92]                | 2.37 [2.10–2.63]| 9.7 (0–20)  | 8.0 (1–19)  | 7.2 (0–18)  |
| 23  | 2.03 [1.65–2.37]             | 0.84 [0.68–0.98]                | 2.40 [2.11–2.65]| 3.3 (0–11)  | 3.6 (0–10)  | 5.5 (1–19)  |
| 26A | 1.98 [1.58–2.36]             | 0.81 [0.70–0.97]                | 2.39 [2.07–2.70]| Ref         | Ref         | Ref         |
| 26A*| 2.02 [1.57–2.29]             | 0.83 [0.70–0.96]                | 2.48 [2.11–2.65]| 3.3 (1–5)   | 2.1 (0–5)   | 3.0 (0–9)   |
| 26B | 1.93 [1.52–2.37]             | 0.82 [0.68–0.96]                | 2.39 [2.08–2.73]| 3.2 (0–8)   | 2.8 (0–7)   | 3.3 (0–10)  |
| 26C | 1.96 [1.62–2.40]             | 0.83 [0.68–1.00]                | 2.33 [2.09–2.69]| 3.1 (0–7)   | 2.7 (0–13)  | 3.7 (0–13)  |
| 27A | 1.86 [1.39–2.26]             | 0.75 [0.6–0.87]                 | 2.45 [2.1–2.84]| 8.2 (1–18)  | 9.3 (1–34)  | 7.0 (0–36)  |
| 27B | 1.97 [1.54–2.45]             | 0.82 [0.67–0.97]                | 2.41 [2.1–2.81]| 3.9 (0–10)  | 3.0 (0–6)   | 4.7 (0–14)  |
| 30  | 1.83 [1.48–2.29]             | 0.79 [0.63–0.95]                | 2.42 [2.1–2.71]| 4.2 (0–9)   | 3.8 (0–12)  | 3.3 (0–9)   |
| 31  | 1.77 [1.42–2.26]             | 0.77 [0.61–0.91]                | 2.42 [2.1–2.65]| 9.0 (2–17)  | 8.0 (2–16)  | 5.7 (0–15)  |
| 32  | 1.83 [1.43–2.25]             | 0.77 [0.63–0.77]                | 2.44 [2.13–2.73]| 7.2 (1–14)  | 7.6 (1–14)  | 4.1 (0–10)  |
| 48  | 1.74 [1.29–2.17]             | 0.75 [0.58–0.83]                | 2.35 [2.08–2.76]| 13.2 (3–23)| 12.7 (5–20)| 5.9 (0–16)  |

Data are presented as median [interquartile range] and mean absolute relative difference (minimum–maximum). Significant differences in MBF and MFR measurements as compared to the reference protocol are indicated with * (P<0.004). MBF, myocardial blood flow; MFR, myocardial flow reserve.

There are several limitations to this study that should be recognized. First, it was not possible to evaluate the effect of different temporal sampling protocols on the diagnostic accuracy due to the lack of a reference standard and the relatively small sample size. However, we did use an optimized temporal sampling protocol suggested by Lee et al. as a reference and performed a pair-wise comparison, limiting the need for a large sample size.

Secondly, we used a relatively low Rb-82 activity (740 MBq) as compared to the generally recommended activity of 1110 MBq. This relatively low amount of activity is sufficient for MBF quantification using the Vereos PET scanner which contains sensitive silicon photomultipliers with digital readout. Higher activities than 740 MBq will presumably result in better count statistics during the tissue phase and could therefore result in a better image quality. However, higher activities may hamper blood flow quantification when using PET scanners with photomultiplier tubes that have a low count-rate performance. If the activities administered exceed the dynamic range of the PET scanner, it will lead to an underestimation of the count-rate during the first-pass phase which will influence the TAC and therefore alter flow measurements. Nevertheless, if we had used a higher activity in all our patients, the count statistics during the tissue phase would be better which would possibly result in less MBF variation when using protocols with shorter time frames in the tissue phase as compared to the reference protocol. However, as previous studies showed that there is no added value in using shorter time frames during the tissue phase, we do not recommend these protocols.

Finally, we tested temporal sampling protocols only using the 1-TCM of Lortie et al. as this model is most commonly used for Rb-82. Therefore, we did not include other 1-TCMs with different extraction functions or other compartmental models such as the two-compartment model and the retention model. The retention model is a simpler model as compared to the 1-TCM as it "does not use TACs, but instead integrates arterial input and myocardial uptake over the first 2 and the following 5 minutes, respectively, after tracer injection." It was already shown that the use of the retention model resulted in differences in stress MBF when compared to the 1-TCM in combination with the ROI methodology and therefore the two models cannot be used interchangeably.

---

**Journal of Nuclear Cardiology**

Koenders et al 1737

Volume 29, Number 4;1729–41 Effect of temporal sampling on MBF
NEW KNOWLEDGE GAINED

This manuscript provides new insights and has several clinical consequences. First, one should be cautious in using different temporal sampling protocols in PET imaging as we found significant differences for rest and stress MBF measurements in the myocardium as a whole but also on a regional level. It seems that MFR is less dependent on temporal sampling (this study) and also on other technical variations. Therefore, MFR seems to be a more suitable parameter to be used between centers and for multicentre trials. To use rest and stress MBF among multiple sites in the detection of CAD and in multicentre trials, harmonization of all technical aspects such as temporal sampling is necessary.

CONCLUSIONS

Various temporal sampling protocols for MBF and MFR quantification using Rb-82 PET result in different MBF values. MFR measurements were more robust to different temporal sampling protocols. Hence, we recommend using MFR instead of MBF measurements, especially when employed at different centers and in multicenter trials.

Table 4. Flow values in the LAD territory and mean absolute relative differences for all 14 protocols in comparison to the reference protocol that was post-processed twice (26A and 26A*).

| LAD | Flow values | Mean absolute relative difference |
|-----|-------------|----------------------------------|
|     | Stress MBF (mL/min/g) | Rest MBF (mL/min/g) | MFR | Stress MBF (%) | Rest MBF (%) | MFR (%) |
| 14  | 1.96 [1.53–2.39] | 0.83 [0.63–0.93] | 2.28 [2.05–2.90] | 5.0 (1–11) | 5.8 (0–18) | 10.0 (1–23) |
| 16  | 1.95 [1.49–2.41] | 0.80 [0.62–0.92] | 2.41 [2.10–2.87] | 4.5 (0–10) | 6.2 (1–27) | 9.8 (0–46) |
| 18  | 1.97 [1.56–2.38] | 0.84 [0.70–0.97] | 2.41 [2.06–2.89] | 3.9 (0–15) | 4.9 (1–14) | 6.6 (0–15) |
| 20  | 1.94 [1.51–2.32] | 0.80 [0.68–0.95] | 2.43 [2.16–2.80] | 4.4 (1–14) | 5.0 (0–12) | 6.7 (0–19) |
| 22  | 1.88 [1.38–2.31]* | 0.76 [0.57–0.89]* | 2.44 [2.12–2.83] | 7.9 (0–16) | 9.1 (0–35) | 11.4 (0–34) |
| 23  | 2.00 [1.52–2.34] | 0.82 [0.68–0.99] | 2.37 [2.09–2.75] | 3.8 (1–13) | 4.2 (0–10) | 6.7 (0–21) |
| 26A | 2.00 [1.48–2.28] | 0.80 [0.72–0.94] | 2.41 [2.09–2.67] | Ref | Ref | Ref |
| 26A*| 1.96 [1.50–2.22] | 0.82 [0.71–0.94] | 2.37 [2.02–2.65] | 3.3 (0–7) | 2.2 (0–6) | 4.1 (0–10) |
| 26B | 1.94 [1.48–2.29] | 0.82 [0.67–0.94] | 2.43 [2.01–2.75] | 3.1 (0–9) | 4.1 (0–11) | 4.8 (0–13) |
| 26C | 1.95 [1.48–2.36] | 0.84 [0.69–0.97] | 2.35 [1.99–2.76] | 2.9 (0–10) | 4.2 (0–16) | 4.5 (0–17) |
| 27A | 1.84 [1.41–2.26]* | 0.75 [0.59–0.86]* | 2.47 [2.07–2.73] | 7.5 (1–19) | 8.8 (0–20) | 6.5 (0–23) |
| 27B | 1.94 [1.48–2.39] | 0.83 [0.63–0.96] | 2.49 [2.09–2.83] | 3.8 (0–10) | 4.5 (0–16) | 6.3 (0–15) |
| 30  | 1.85 [1.40–2.29] | 0.81 [0.60–0.92]* | 2.47 [2.14–2.70] | 4.1 (1–10) | 5.3 (0–20) | 6.2 (1–25) |
| 31  | 1.81 [1.39–2.21]* | 0.77 [0.58–0.84]* | 2.39 [2.14–2.69] | 7.5 (1–17) | 9.0 (2–23) | 7.2 (1–20) |
| 32  | 1.87 [1.38–2.25]* | 0.76 [0.60–0.85]* | 2.41 [2.12–2.76] | 6.9 (1–15) | 9.1 (2–24) | 6.4 (1–22) |
| 48  | 1.78 [1.33–2.12]* | 0.74 [0.56–0.80]* | 2.36 [2.08–2.78] | 11.7 (3–23) | 13.1 (1–28) | 9.0 (2–23) |

Data are presented as median [interquartile range] and mean absolute relative difference (minimum–maximum). Significant differences in MBF and MFR measurements as compared to the reference protocol are indicated with * (P<0.004). MBF, myocardial blood flow; MFR, myocardial flow reserve.

Disclosures

None of the authors have anything to disclose.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

APPENDIX

See Tables 4, 5, and 6.
Table 5. Flow values in the LCX territory and mean absolute relative differences for all 14 protocols in comparison to the reference protocol that was post-processed twice (26A and 26A*).

|   | Stress MBF (mL/min/g) | Rest MBF (mL/min/g) | MFR | Stress MBF (%) | Rest MBF (%) | MFR (%) |
|---|----------------------|---------------------|-----|---------------|--------------|---------|
| 14| 1.87 [1.51–2.26]     | 0.85 [0.69–1.00]   | 2.29 [1.86–2.85] | 4.2 (0–13) | 4.7 (0–14) | 6.9 (1–19) |
| 16| 1.82 [1.46–2.21]     | 0.82 [0.67–1.00]   | 2.31 [1.92–2.82] | 4.5 (1–14) | 5.3 (0–16) | 6.4 (0–20) |
| 18| 1.86 [1.56–2.20]     | 0.88 [0.74–1.00]   | 2.19 [1.98–2.85] | 4.2 (0–14) | 4.9 (0–15) | 7.4 (1–15) |
| 20| 1.79 [1.49–2.17]     | 0.86 [0.69–1.01]   | 2.33 [1.81–2.78] | 3.6 (0–10) | 4.2 (0–13) | 5.2 (0–26) |
| 22| 1.68 [1.29–2.10]     | 0.78 [0.61–0.94]   | 2.19 [1.94–2.79] | 11.3 (1–22) | 10.2 (0–28) | 8.3 (1–18) |
| 23| 1.92 [1.52–2.19]     | 0.87 [0.71–1.01]   | 2.17 [1.93–2.77] | 3.3 (0–7)  | 4.1 (0–13) | 5.4 (0–16) |
| 26A| 1.86 [1.45–2.21]    | 0.85 [0.72–0.98]   | 2.12 [1.82–2.94] | Ref | Ref | Ref |
| 26A*| 1.87 [1.52–2.17]    | 0.85 [0.73–0.96]   | 2.16 [1.89–2.93] | 3.3 (0–7)  | 1.9 (0–8)  | 3.7 (1–8)  |
| 26B| 1.79 [1.40–2.19]     | 0.85 [0.70–0.96]   | 2.16 [1.82–2.97] | 3.6 (0–7)  | 3.6 (0–11) | 3.5 (0–10) |
| 26C| 1.85 [1.46–2.28]     | 0.86 [0.71–1.04]   | 2.17 [1.93–2.76] | 3.6 (0–10) | 3.4 (0–13) | 5.1 (0–12) |
| 27A| 1.73 [1.39–2.06]     | 0.79 [0.62–0.94]   | 2.25 [2.00–2.85] | 8.8 (0–16) | 9.6 (1–25) | 6.8 (0–22) |
| 27B| 1.87 [1.46–2.33]     | 0.87 [0.70–0.96]   | 2.16 [1.91–2.94] | 4.4 (1–13) | 3.7 (0–8)  | 4.5 (0–15) |
| 30 | 1.75 [1.38–2.18]    | 0.81 [0.65–0.99]   | 2.22 [1.89–2.99] | 4.6 (0–10) | 5.3 (0–16) | 4.2 (0–16) |
| 31 | 1.61 [1.31–2.08]    | 0.79 [0.61–0.92]   | 2.21 [1.95–2.75] | 9.7 (1–19) | 9.1 (1–22) | 7.7 (2–15) |
| 32 | 1.69 [1.32–2.15]    | 0.79 [0.63–0.93]   | 2.26 [1.92–2.96] | 7.4 (0–15) | 8.7 (2–20) | 5.1 (0–18) |
| 48 | 1.61 [1.22–2.00]    | 0.73 [0.58–0.85]   | 2.18 [1.93–2.93] | 13.9 (1–23) | 14.3 (6–26) | 6.4 (1–15) |

Data are presented as median [interquartile range] and mean absolute relative difference (minimum–maximum). Significant differences in MBF and MFR measurements as compared to the reference protocol are indicated with * (P<0.004). MBF, myocardial blood flow; MFR, myocardial flow reserve.

Table 6. Flow values in the RCA territory and mean absolute relative differences for all 14 protocols in comparison to the reference protocol that was post-processed twice (26A and 26A*).

|   | Stress MBF (mL/min/g) | Rest MBF (mL/min/g) | MFR | Stress MBF (%) | Rest MBF (%) | MFR (%) |
|---|----------------------|---------------------|-----|---------------|--------------|---------|
| 14| 2.14 [1.91–2.14]     | 0.91 [0.76–1.07]   | 2.62 [2.09–2.87] | 6.9 (0–16) | 5.4 (0–19) | 7.8 (0–15) |
| 16| 2.12 [1.83–2.70]     | 0.94 [0.71–1.06]   | 2.64 [2.09–2.87] | 6.5 (0–18) | 5.9 (0–15) | 7.7 (1–19) |
| 18| 2.33 [1.94–2.91]     | 0.96 [0.75–1.18]   | 2.54 [2.09–2.93] | 4.5 (0–19) | 5.1 (0–18) | 6.8 (0–19) |
| 20| 2.17 [1.86–2.59]     | 0.93 [0.69–1.04]   | 2.46 [2.30–2.98] | 5.7 (0–14) | 4.9 (0–16) | 5.3 (0–16) |
| 22| 1.96 [1.66–2.60]     | 0.85 [0.66–0.98]   | 2.50 [2.13–2.90] | 12.2 (0–27) | 10.6 (1–22) | 8.6 (0–28) |
| 23| 2.22 [1.89–2.72]     | 0.95 [0.71–1.09]   | 2.41 [2.15–2.91] | 4.4 (0–17) | 3.7 (0–10) | 5.8 (0–22) |
| 26A| 2.38 [1.86–2.72]    | 0.97 [0.71–1.10]   | 2.40 [2.15–3.08] | Ref | Ref | Ref |
| 26A*| 2.35 [1.94–2.76]    | 0.97 [0.72–1.08]   | 2.41 [2.23–3.03] | 3.7 (1–11) | 3.4 (0–7)  | 3.2 (0–14) |
| 26B| 2.22 [1.87–2.67]     | 0.94 [0.71–1.11]   | 2.43 [2.04–2.99] | 5.1 (0–16) | 4.1 (0–13) | 4.8 (1–16) |
| 26C| 2.31 [1.84–2.68]     | 0.95 [0.69–1.10]   | 2.34 [2.20–2.84] | 3.4 (0–12) | 3.3 (0–14) | 5.6 (0–23) |
| 27A| 2.01 [1.75–2.59]     | 0.87 [0.66–1.01]   | 2.42 [2.18–2.94] | 10.6 (0–22) | 9.6 (2–19) | 6.3 (0–19) |
### Table 6 continued

| RCA | Flow values | Mean absolute relative difference |
|-----|-------------|-----------------------------------|
|     | Stress MBF (mL/min/g) | Rest MBF (mL/min/g) | MFR | Stress MBF (%) | Rest MBF (%) | MFR (%) |
| 27B | 2.23 [1.83-2.79] | 0.94 [0.68-1.10] | 2.53 [2.06-2.97] | 5.5 (1-14) | 4.0 (0-12) | 6.9 (0-19) |
| 30  | 2.19 [1.80-2.57]* | 0.90 [0.67-1.03]* | 2.51 [2.14-3.06] | 6.3 (1-19) | 6.9 (0-18) | 5.5 (0-15) |
| 31  | 2.02 [1.73-2.50]* | 0.85 [0.64-1.00]* | 2.43 [2.22-2.96] | 11.4 (3-21) | 10.8 (0-22) | 6.9 (1-20) |
| 32  | 2.07 [1.73-2.49]* | 0.88 [0.66-1.01]* | 2.44 [2.18-2.99] | 9.7 (3-21) | 9.6 (0-21) | 5.7 (0-18) |
| 48  | 1.95 [1.59-2.40]* | 0.80 [0.61-0.93]* | 2.40 [2.22-3.05] | 16.4 (5-31) | 15.9 (7-29) | 7.5 (0-24) |

Data are presented as median [interquartile range] and mean absolute relative difference (minimum-maximum).

Significant differences in MBF and MFR measurements as compared to the reference protocol are indicated with * (P < 0.004).

**MBF**, myocardial blood flow; **MFR**, myocardial flow reserve

### References

1. Ziadi MC, deKemp RA, Williams KA, Guo A, Chow BJ, Renaud JM et al (2011) Impaired myocardial blood flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. Cardiac Imaging 58:740-48
2. Sciagra R, Passeri A, Bucerius J, Verberne HJ, Slart OL, Riemer HJA, Lindner O et al (2016) Clinical use of quantitative cardiac perfusion PET: Rationale, modalities and possible indications. Position paper of the cardiovascular committee of the European association of nuclear medicine (EANM). Eur J Nucl Med Mol Imaging 43:1530-45
3. Murthy V, Bateman T, Beanlands R, Berman D, Borges-Neto S, Chareonthaitawee P et al (2018) Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Cardiol 25:269-97
4. Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G et al (2011) Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 124:2215-24
5. Patel KK, Sperutas JA, Chan PS, Sperry BW, Al Badarin F, Kenndy KP et al (2020) Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. Eur Heart J 41:759-68
6. Klein R, Oceaneau A, deKemp R (2017) Time-frame sampling for 82Rb PET flow quantification: Towards standardization of clinical protocols. J Nucl Cardiol 24:1530-34
7. Sciagra R, Luberink M, Hyafil F, Saraste A, Slart OL, Riemer HJA, Agostini D et al (2020) EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-05046-9
8. Klein R, Beanlands R, deKemp R (2018) Quantification of myocardial blood flow and flow reserve: Technical aspects. J Nucl Cardiol 17:555-70
9. Moody J, Lee B, Corbett J, Ficaro E, Murthy V (2015) Precision and accuracy of clinical quantification of myocardial blood flow by dynamic PET: A technical perspective. J Nucl Cardiol 22:935-51
10. Lee B, Moody J, Weinberg R, Corbett J, Ficaro E, Murthy V (2017) Optimization of temporal sampling for 82rubidium PET myocardial blood flow quantification. J Nucl Cardiol 24:1517-29
11. Koenders SS, van Dijk JD, Jager PL, Ottervanger JP, Slump CH, van Dalen JA (2019) How to detect and correct myocardial creep in myocardial perfusion imaging using rubidium-82 PET? J Nucl Cardiol 26:729-34
12. Koenders SS, van Dijk JD, Jager PL, Ottervanger JP, Slump CH, van Dalen JA (2019) Impact of regadenoson-induced myocardial creep on dynamic rubidium-82 PET myocardial blood flow quantification. J Nucl Cardiol 26:719-28
13. Lortie M, Beanlands R, Yoshinaga K, Klein R, DaSilva J, deKemp R (2007) Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 34:1765-74
14. Moody JB, Murthy VL, Lee BC, Corbett JR, Ficaro EP (2015) Variance estimation for myocardial blood flow by dynamic PET. IEEE Trans Med Imaging 34:2343-53
15. Farhad H, Dunet V, Bachelard K, Allenbach G, Kaufmann PA, Prior JO (2013) Added prognostic value of myocardial blood flow quantitation in rubidium-82 positron emission tomography imaging. Eur Heart J Cardiovasc Imaging 14:1203-10
16. Danad I, Uusitalo V, Kero T, Saraste A, Rajimakers PG, Lammersma AA et al (2014) Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease cutoff values and diagnostic accuracy of quantitative [O-15]H2O PET imaging. J Am Coll Cardiol 64:1464-75
17. Hajiiri MM, Leavitt MB, Zheng H, Spooner AE, Fischman AJ, Gewirtz H (2009) Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location. JACC Cardiovasc Imaging 2:751-58
18. Gupta A, Taqueti VR, van de Hoef TP, Tim P, Bajaj NS, Bravo PE, Murthy VL et al (2017) Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. Circulation 136:2325-36
19. Murthy VL, Lee BC, Sitek A, Naya M, Moody J, Polavarapu V et al (2014) Comparison and prognostic validation of multiple methods of quantification of myocardial blood flow with 82Rb PET. J Nucl Med 55:1952-58
20. Tahari AK, Lee A, Rajaram M, Fukushima K, Lodge MA, Lee BC et al (2014) Absolute myocardial flow quantification with (82)rb PET/CT: Comparison of different software packages and methods. Eur J Nucl Med Mol Imaging 41:126-35
21. Armstrong I, Tonge C, Arumugam P (2014) Impact of point spread function modeling and time-of-flight on myocardial blood flow and myocardial flow reserve measurements for rubidium-82 cardiac PET. J Nucl Cardiol 21:467-74
22. van Dijk J, Jager P, van Osch J, Khodaverdi M, van Dalen J (2019) Comparison of maximal rubidium-82 activities for myocardial blood flow quantification between digital and conventional PET systems. J Nucl Cardiol 26:1286-91
23. Hoff CM, Strensen J, Christensen NL, Bouchelouche K, Tolbod L (2020) Activity regimes for 82Rb cardiac PET: Effects on absolute MBF and MPI. J Nucl Cardiol. https://doi.org/10.1007/s12350-020-02266-2
24. Renaud JM, Yip K, Guimond J, Trottier M, Pibarot P, Turcotte E et al (2017) Characterization of 3-dimensional PET systems for accurate quantification of myocardial blood flow. J Nucl Med 58:103-09
25. Prior JO, Allenbach G, Valenta I, Kosinski M, Burger C, Verdun FR et al (2012) Quantification of myocardial blood flow with 82 rb positron emission tomography: Clinical validation with 15 O-water. Eur J Nucl Med Mol Imaging 39:1037-47
26. Herrero P, Markham J, Shelton ME, Bergmann SR (1992) Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. Circ Res 70:496-07
27. Yoshida K, Mullani N, Gould KL (1996) Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med 37:1701-12
28. Herrero P, Markham J, Shelton ME, Weinheimer CJ, Bergmann SR (1990) Noninvasive quantification of regional myocardial perfusion with rubidium-82 and positron emission tomography. Exploration of a mathematical model. Circulation 82:1377-86
29. Yoshinaga K, Klein R, Tamaki N (2010) Generator-produced rubidium-82 positron emission tomography myocardial perfusion imaging—From basic aspects to clinical applications. J Cardiol 55:163-73
30. Johnson NP, Gould KL (2015) Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc Imaging 8:438-47

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.